DOCSLIB.ORG

Translating Molecular and Neuroendocrine Findings in PTSD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Translating Molecular and Neuroendocrine Findings in PTSD ACCEPTED MANUSCRIPT DePierro et al. Supplement Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies Supplemental Information Table S1. Extended summary of candidate PTSD pharmacotherapies Treatment Target Rationale for use in Effect Status Reverse Translation Engagement PTSD Size SSRIs (1, 2) Serotonergic M ainly to treat 0.48 A Perhaps PTSD involves (several 5-HT comorbid symptoms; diminished capacity to receptors) perhaps PTSD involves downregulate 5-HT1B receptors; diminished capacity to alterations of serotonergic downregulate 5-HT1B receptors in the amygdala; receptors MANUSCRIPT connection of serotonin, trauma, and hippocampal volume Venlafaxine (2) Monoaminergic Treatment of 0.48 B Not thoroughly investigated (serotonergic, symptoms overlapping norepinephrinergic) with depression; adrenergic involvement Trazodone (2) Monoaminergic I mprove sleep n/a B, but Not thoroughly investigated (5-HT2; alpha-1 disturbance may for antagonist) improve symptoms comorbid insomnia only Atypical Dopaminergic treat psychotic-like 0.1-0.41 C Not thoroughly investigated Antipsychotics (2) (D2 antagonism)ACCEPTED symptoms Benzodiazepines GABAergic treat anxiety 0.28 C Alterations of GABA (2) (GABA-A positive receptors allosteric modulator) 1 ACCEPTED MANUSCRIPT DePierro et al. Supplement Treatment Target Rationale for use in Effect Status Reverse Translation Engagement PTSD Size Clonidine/ Adrenergic Reduction of -0.08 C Modest effects suggest that Guanfacine (3-5) (alpha-2-agonist) hyperadrenergic PTSD symptom improvement activity may additionally require manipulation of other targets Prazosin (2, 6-8) Adrenergic Reduction of 0.78 C Specific effects on nightmares (alpha-1-antagonist) hyperadrenergic and sleep suggest these activity symptoms are underpinned by noradrenergic dysregulation Propranolol (9-11) Adrenergic Reduction of n/a C Modest effects in preventing (beta-2-antagonist) hyperadrenergic consolidation of aversive activity with the memories in PTSD compared to specific intent of robust effects in preclinical blocking studies highlights gap in reconsolidation of fear translatability of fear models to memory; possibleMANUSCRIPT PTSD treatment prophylactic immediately after trauma Topiramate (12) GABAergic? Use of other 1.20 C Stress-activated limbic (voltage-gated anticonvulsants in kindling effect of PTSD sodium channels, refractory PTSD; avoid voltage-activated side effects seen with calcium channels, SSRIs GABA-A, AMPA) Typical Monoaminergic treat psychotic-like n/a C Not thoroughly investigated Antipsychotics (2) (5-HT2A symptoms antagonism, fast D2 dissociation, 5ACCEPTED- HT1A agonism) 2 ACCEPTED MANUSCRIPT DePierro et al. Supplement Treatment Target Rationale for use in Effect Status Reverse Translation Engagement PTSD Size Mirtazapine Monoaminergic successful treatment 0.27 C-D Not thoroughly investigated (13, 14) (Adrenergic, of other anxiety and antihistamine) sleep disorders Yohimbine (15) Adrenergic Since this n/a D Intrusive and hyperarousal (alpha-2-antagonist) medication induces symptoms may be underpinned flashbacks it may by noradrenergic dysregulation; enhance arousal during enhancing these symptoms in exposure therapy, psychotherapy do not promote facilitating extinction symptom reduction learning Bupropion (16) Monoaminergic SSRIs have been 0.21 D Not thoroughly investigated (dopaminergic, helpful but have more norepinephrinergic) side-effects than Bupropion Gabapentin Anxiety Reduction of anxietyMANUSCRIPT n/a D Not thoroughly investigated symptoms, after trauma to prevent mechanism PTSD; decrease unknown (voltage comorbid symptoms gated calcium such as alcohol use, channel) sleep disorder, which may contribute to PTSD severity Nefazodone (17) Monoaminergic Anxiolytic helpful n/a D1 Not thoroughly investigated (5-HT2; alpha-1 with sleep without side antagonist) effect burden of SSRIs MAOIs (2) Monoaminergic antidepressant 0.21 D1 Not thoroughly investigated ACCEPTEDeffects TCAs (2) Monoaminergic antidepressant 0.36 D1 Not thoroughly investigated effects 3 ACCEPTED MANUSCRIPT DePierro et al. Supplement Treatment Target Rationale for use in Effect Status Reverse Translation Engagement PTSD Size Riluzole (16, 18) Glutamatergic; because of anti- n/a E Not specific to PTSD, but in GABAergic; glutamatergic (NMDA) GAD, correlation between excitotoxic target, trialed in other improvement in anxiety pathways, anxiety disorders with symptoms and increase in mitochondrial some signal hippocampal volume function, fat metabolism, sodium channel function, calcium-dependent potassium currents (VGNC, kainate and NMDAR, GABA-A receptors) buprenex/vivitrol Opiate (kappa Observation that n/a E1 Development of KOR PET (19, 20) opioid receptor patients self-medicate radiotracer which lead to finding antagonist) with opioids to MANUSCRIPT that KOR in ventral striatal alleviate PTSD circuit involved in trauma- symptoms; preclinical related dysphoria, perhaps data demonstrating mediated by HPA improved behavioral responses to stress Hydrocortisone HPA axis enhancement of n/a E1 Elevated or diminished levels (21) synthetic hormone reduced glucocorticoid of glucocorticoids during a replacement signaling to improve critical window immediately stress response following trauma may cause immediately following permanent cytoarchitectural trauma to prevent changes which contribute to ACCEPTEDPTSD; may have pathophysiology effects on memory reconsolidation 4 ACCEPTED MANUSCRIPT DePierro et al. Supplement Treatment Target Rationale for use in Effect Status Reverse Translation Engagement PTSD Size Hydrocortisone- HPA axis facilitation of n/a E1 Hydrocortisone may diminish augmented exposure- synthetic hormone extinction, therapeutic fear during reactivation of therapy (22) administration prior reconsolidation memory which allows patient to to exposure sessions more meaningfully engage material Pregnenolone (23) GABAergic, Low levels of the n/a E1 Trials still underway unknown (GABA- hormone observed in A; downstream PTSD; GABA-A targets of steroid receptors metabolites) downregulated in chronic stress Neuropeptide Y HPA axis; regulates HPA axis, n/a E1 Trials still underway (24) neurogenesis may contribute resilience during uncontrollable stress;MANUSCRIPT levels found to be low in PTSD Ketamine Glutamatergic observational studies n/a E1 Glutamatergic pathway in (25, 26) system; dendritic that patients who PTSD still under investigation, spine? (NMDA received ketamine after but likely related to the effect of receptor antagonist) trauma may have a chronic stress on learning and lower incidence of memory; ketamine may rapidly PTSD promote neuroplasticity in PTSD ACCEPTED 5 ACCEPTED MANUSCRIPT DePierro et al. Supplement Treatment Target Rationale for use in Effect Status Reverse Translation Engagement PTSD Size MDMA-assisted Creation of ideal Fostering trust in the 0.8-2.8 E1 Probing the pathway of psychotherapy setting for a therapeutic alliance, opening/closing of critical (27, 28) psychotherapeutic maintaining optimal periods of plasticity experience that leads arousal during memory to meaningful re- retrieval and appraisal of trauma reconsolidation, feelings of self- compassion 7-Keto DHEA HPA axis/GABA- DHEA may promote n/a E1 Results of trial not yet (29) A antagonist, resilience after trauma published positive NMDA modulation, metabolizes cortisol Pregabalin Glutamatergic Has been helpful in n/a E1 Plan is to probe (voltage-gated alcohol use disorderMANUSCRIPT endophenotype with genetic calcium channel that plus GAD in the past variant glutamate transporter modulates glutamate so may be helpful for transporter 1) GAD plus PTSD; case reports of adjunctive pregabalin ameliorating PTSD symptoms GSK561679 HPA axis PTSD 0.277 in E1 Towards development of (Verucerfont) (CRF-1 antagonist) endophenotype with child abuse endophenotypes and (30) exposure to child abuse NR3C1 personalized medicine and also have a SNP of methyl- the receptor gene have ation group CRF1 receptor ACCEPTEDhyperactivity/ suppresses ACTH response to stress 6 ACCEPTED MANUSCRIPT DePierro et al. Supplement Treatment Target Rationale for use in Effect Status Reverse Translation Engagement PTSD Size Methylene blue Stimulates enhance extinction n/a E1 Trials still underway (+imaginal exposure) mitochondrial learning (31) oxidative metabolism and cerebral oxygen consumption; enhances memory consolidation/ extinction D-cycloserine- Glutamatergic? Induce LTP during 0.61 E1 Relevance of NMDA- assisted exposure (NDMA agonist) therapy and enhance mediated learning and plasticity therapy extinction of memory during exposure therapy (32) Oxytocin Glucocorticoid; reduced intensity of n/a E1 Oxytocin receptor methylation (33) social bonding fear memory by MANUSCRIPT may be implicated in (oxytocin receptors; decreasing amygdala pathophysiology; Oxytocin’s increase social activation; increased role in critical period plasticity, cognition/feelings of pro-social behavior regulation of HPA system in closeness) lacking in PTSD PTSD; may mediate social cognition deficits in PTSD Cannabidiol Endocannabinoid patients have n/a E1 Involvement of the ECB (34, 35) (inhibition of the increased CB1 system in the expression of uptake or of the receptors which may be contextual fear conditioning; a enzymatic caused by a chronic potential new target in the degradation of deficiency of the adenosinergic system endocannabinoids) endocannabinoid AEA CB1 agonist Endocannabinoid enhance fear n/a E1 Trials still underway (Nabilone) ACCEPTEDextinction
Load more

Recommended publications
  • British Journal of Nutrition (2013), 110, 1524–1533 Doi:10.1017/S0007114513000743 Q the Authors 2013
    Downloaded from British Journal of Nutrition (2013), 110, 1524–1533 doi:10.1017/S0007114513000743 q The Authors 2013 https://www.cambridge.org/core The dopamine b-hydroxylase inhibitor, nepicastat, suppresses chocolate self-administration and reinstatement of chocolate seeking in rats Alessandro Zaru1, Paola Maccioni1, Giancarlo Colombo1 and Gian Luigi Gessa1,2* . IP address: 1Neuroscience Institute, National Research Council of Italy, Section of Cagliari, S.S. 554 km. 4,500, I-09042 Monserrato (CA), Italy 170.106.40.40 2Department of Biomedical Sciences, University of Cagliari, Monserrato (CA), Italy (Submitted 26 July 2012 – Final revision received 5 February 2013 – Accepted 6 February 2013 – First published online 8 April 2013) , on 28 Sep 2021 at 03:11:02 Abstract Craving for chocolate is a common phenomenon, which may evolve to an addictive-like behaviour and contribute to obesity. Nepicastat is a selective dopamine b-hydroxylase (DBH) inhibitor that suppresses cocaine-primed reinstatement of cocaine seeking in rats. We verified whether nepicastat was able to modify the reinforcing and motivational properties of a chocolate solution and to prevent the reinstatement of chocolate seeking in rats. Nepicastat (25, 50 and 100 mg/kg, intraperitoneal) produced a dose-related inhibition of operant self-administration of the chocolate solution in rats under fixed-ratio 10 (FR10) and progressive-ratio schedules , subject to the Cambridge Core terms of use, available at of reinforcement, measures of the reinforcing and motivational properties of the chocolate solution, respectively. The effect of nepica- stat on the reinstatement of chocolate seeking was studied in rats in which lever-responding had been extinguished by removing the chocolate solution for approximately 8 d.
    [Show full text]
  • JPET #212357 1 TITLE PAGE Effects of Pharmacologic Dopamine Β
    JPET Fast Forward. Published on May 9, 2014 as DOI: 10.1124/jpet.113.212357 JPETThis Fast article Forward. has not been Published copyedited and on formatted. May 9, The 2014 final as version DOI:10.1124/jpet.113.212357 may differ from this version. JPET #212357 TITLE PAGE Effects of Pharmacologic Dopamine β-Hydroxylase Inhibition on Cocaine-Induced Reinstatement and Dopamine Neurochemistry in Squirrel Monkeys Debra A. Cooper, Heather L. Kimmel, Daniel F. Manvich, Karl T. Schmidt, David Weinshenker, Leonard L. Howell Yerkes National Primate Research Center Division of Neuropharmacology and Neurologic Diseases (D.A.C., H.L.K., L.L.H.), Department of Pharmacology (H.L.K., L.L.H.), Department of Human Genetics (D.A.C., D.F.M, K.T.S., D.W.), and Department of Psychiatry and Behavioral Sciences (L.L.H.) Emory University, Atlanta, Georgia Downloaded from jpet.aspetjournals.org at ASPET Journals on September 24, 2021 1 Copyright 2014 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on May 9, 2014 as DOI: 10.1124/jpet.113.212357 This article has not been copyedited and formatted. The final version may differ from this version. JPET #212357 RUNNING TITLE PAGE Running Title: Effects of Dopamine β-Hydroxylase Inhibition in Monkeys Correspondence: Dr LL Howell, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, USA, Tel: +1 404 727 7786; Fax: +1 404 727 1266; E- mail: [email protected] Text Pages: 19 # Tables: 1 # Figures: 5 # References: 51 Abstract: 250 words Introduction: 420 words Discussion: 1438 words Downloaded from Abbreviations aCSF artificial cerebrospinal fluid DA dopamine jpet.aspetjournals.org DBH dopamine β-hydroxylase EDMax maximally-effective unit dose of cocaine (self-administration) EDPeak maximally-effective dose of pre-session drug prime (reinstatement) at ASPET Journals on September 24, 2021 FI fixed-interval FR fixed-ratio HPLC high-performance liquid chromatography i.m.
    [Show full text]
  • Disulfiram Attenuates Drug-Primed Reinstatement of Cocaine Seeking Via Inhibition of Dopamine B-Hydroxylase
    Neuropsychopharmacology (2010) 35, 2440–2449 & 2010 Nature Publishing Group All rights reserved 0893-133X/10 $32.00 www.neuropsychopharmacology.org Disulfiram Attenuates Drug-Primed Reinstatement of Cocaine Seeking via Inhibition of Dopamine b-Hydroxylase 1,6 1,6 1 1 1 Jason P Schroeder , Debra A Cooper , Jesse R Schank , Megan A Lyle , Meriem Gaval-Cruz , 1 2 3 2,4 3 Yvonne E Ogbonmwan , Nikita Pozdeyev , Kimberly G Freeman , P Michael Iuvone , Gaylen L Edwards , Philip V Holmes5 and David Weinshenker*,1 1 2 Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA; Department of Pharmacology, Emory University 3 4 School of Medicine, Atlanta, GA, USA; Department of Physiology and Pharmacology, University of Georgia, Athens, GA, USA; Department of 5 Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA; Department of Psychology, University of Georgia, Athens, GA, USA The antialcoholism medication disulfiram (Antabuse) inhibits aldehyde dehydrogenase (ALDH), which results in the accumulation of acetaldehyde upon ethanol ingestion and produces the aversive ‘Antabuse reaction’ that deters alcohol consumption. Disulfiram has also been shown to deter cocaine use, even in the absence of an interaction with alcohol, indicating the existence of an ALDH-independent therapeutic mechanism. We hypothesized that disulfiram’s inhibition of dopamine b-hydroxylase (DBH), the catecholamine biosynthetic enzyme that converts dopamine (DA) to norepinephrine (NE) in noradrenergic neurons, underlies the drug’s ability to treat cocaine dependence. We tested the effects of disulfiram on cocaine and food self-administration behavior and drug-primed reinstatement of cocaine seeking in rats. We then compared the effects of disulfiram with those of the selective DBH inhibitor, nepicastat.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Supervised Disulfiram As Adjunct to Psychotherapy in Alcoholism Treatment
    Curr Pharm Des. 2010;16(19):2076-90. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Krampe H , Ehrenreich H . Department of Anaesthesiology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Germany. [email protected] Abstract Supervised intake of the alcohol deterrent (AD) disulfiram has proven to be an effective adjunct to biopsychosocial alcoholism therapy for more than 60 years. This article summarizes disulfiram literature between 1937 and 2000 and reviews 13 clinical trials of disulfiram in alcoholism treatment from the years 2000 to 2008. After giving an update of general safety issues and recent case reports concerning safety problems with disulfiram, we focus on the introduction of psychotherapeutic application of supervised disulfiram. The results of our review show: (1) Disulfiram proved to be an effective therapeutic tool in all clinical studies published from 2000 to 2008. (2) Comparisons with other pharmacological agents - naltrexone, acamprosate, topiramate and gamma-hydroxybutyrate - indicate that disulfiram was equal in two trials but superior in the majority of trials. (3) Therapy programs that make use of the psychological effects of supervised disulfiram have - independently of the dose - better results than programs that neglect psychological effects. As a consequence, we suggest that supervised low-dose disulfiram (not more than 100mg/d), will show highest success when it is carefully integrated into psychotherapeutic alcoholism therapy. The major program of psychotherapy with disulfiram comprises the steps "Initial psychoeducation about the effect of disulfiram and its therapeutic implications", "Advanced psychoeducation", and "Disulfiram as coping skill and extension of repertoire of coping skills". As psychological mechanisms of supervised disulfiram we suggest: (1) deterrence; (2) (auto)suggestion; (3) therapeutic ritual around (4) a frequently renewed active decision process; (5) continuous reinforcement of a sober lifestyle and development of new coping skills.
    [Show full text]
  • Pharmacotherapy for Stimulant Use Disorders: a Systematic Review
    4 D epartment of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Pharmacotherapy for Stimulant Use Disorders: A Systematic Review August 2018 Prepared for: Investigators: Department of Veterans Affairs Principal Investigator: Veterans Health Administration Brian Chan, MD, MPH Quality Enhancement Research Initiative Co-Investigators: Health Services Research & Development Service Karli Kondo, PhD, MA Washington, DC 20420 Chelsea Ayers, BA Prepared by: Michele Freeman, MPH Jessica Montgomery, MPH Evidence-based Synthesis Program (ESP) Robin Paynter, MLIS Portland VA Health Care System Devan Kansagara, MD, MCR Portland, OR Devan Kansagara, MD, MCR, Director 4 Pharmacotherapy for Stimulant Use Disorders Evidence-based Synthesis Program PREFACE The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for 4 ESP Centers, and each Center has an active University affiliation. Center Directors are recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Centers. The ESP is governed by a Steering Committee comprised of participants from VHA Policy, Program, and Operations Offices, VISN leadership, field-based investigators, and others as designated appropriate by QUERI/HSR&D. The ESP Centers generate evidence syntheses on important clinical practice topics. These reports help: · Develop clinical policies informed by evidence; · Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and · Set the direction for future research to address gaps in clinical knowledge.
    [Show full text]
  • New Horizons for Therapeutics in Drug and Alcohol Abuse
    Pharmacology & Therapeutics 125 (2010) 138–168 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: G. Dusting New horizons for therapeutics in drug and alcohol abuse Bianca Jupp a, Andrew J. Lawrence a,b,⁎ a Florey Neuroscience Institutes, The University of Melbourne, Parkville VIC 3010, Australia b The Centre for Neuroscience, The University of Melbourne, Parkville VIC 3010, Australia article info abstract Keywords: Alcohol, tobacco and illicit drug dependence represents a serious health and social issue within the Addiction community. As drug dependence has become more widely recognized as a clinical disorder and the severity Amphetamine of the problem been fully realized, options available for treatment have grown along with our understanding Cannabis of the neurobiological mechanisms underlying the development and persistence of addiction. Treatment has Cocaine progressed from purely social and behavioral approaches to now encompass pharmacotherapy to attempt to Inhalants Nicotine disrupt the mechanisms underlying these disorders. Despite these advances, many forms of addiction lack effective therapeutics and the prevalence of this disorder remains unacceptably high. As a result, a significant effort within the research community has been dedicated to the identification of novel targets for the development of therapeutics based upon our understanding of the pathological processes underlying addiction. The current review aims to provide an overview of existing and clinically trialed pharmacothera- pies for alcohol, opiate, psychostimulant, nicotine, cannabis and inhalant addictions. Further, we discuss some of the potential targets that have been recently indentified from basic studies that may hold promise for the development of novel treatments. © 2009 Elsevier Inc.
    [Show full text]
  • Poster Abstr Acts May 28 – 31, 2013 Wednesday, May 29, 2013 Poster Session I Regency 1 Ballroom
    NCDEU An Annual Meeting of the ASCP Recognizing Unmet Needs in Psychopharmacology: From Biomarkers to Breakthrough Therapies POSTER ABSTR acTS MAY 28 – 31, 2013 Wednesday, May 29, 2013 Poster Session I Regency 1 Ballroom 1 THE EFFECTS OF BEHAVIORAL PARENT TRAINING AND ACUTE STIMULANT MEDICATION TREATMENT FOR PARENTS WITH ADHD Dara Babinski, M.A.1, James G. Waxmonsky, MD2, William E. Pelham, Jr., PhD, ABPP2 1University of Florida, 2Florida International University Half of families initiating behavioral parent training (BPT) do not improve. Parental ADHD symptoms may reduce the efficacy of BPT (Chronis et al., 2004), but there are no a priori studies of parents meeting full DSM-IV ADHD criteria. Stimulant medication has been shown to improve parenting (Chronis- Tuscano et al., 2008; Waxmonsky et al., in preparation), but it is not known whether there is additional benefit to receiving medication after completing BPT. This study evaluated the efficacy of BPT for parents with ADHD, and also explored the acute effects of medication on parent child interactions. Participants were 12 parents and their children (ages 6-12) who met DSM ADHD criteria. Parents were first stabilized on stimulant medication during weekly visits with study psychiatrists using the ADHD-RS to titrate to optimal dose. Then, parents discontinued medication and were randomly assigned to a 3, 4, or 5 week baseline, during which they provided semiweekly ratings of their impairment (i.e., Sheehan Disability Scale; SDS; Sheehan et al., 1996), parenting (i.e., Alabama Parenting Questionnaire-9; APQ-9; Elgar et al., 2007) and their child’s behavior (i.e., Home Situations Questionnaire; HSQ; Barkley, 1997; Parent Daily Report; PDR; Patterson et al., 1982).
    [Show full text]
  • WO 2007/061529 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 31 May 2007 (31.05.2007) PCT WO 2007/061529 Al (51) International Patent Classification: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, A61K 9/14 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, PCT/US2006/040197 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 13 October 2006 (13.10.2006) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (26) Publication Language: English ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, (30) Priority Data: RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, 11/282,507 18 November 2005 (18.1 1.2005) US GN, GQ, GW, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): SCI- Declarations under Rule 4.17: DOSE PHARMA INC.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]